The RNS® System:
Post-Approval Study Data

NEUROPACE

The Impact of Drug-Resistant Epilepsy

Focal epilepsy is the most common form of drug-resistant epilepsy (DRE), which means that patients' seizures are not controlled by drug therapy. It often results in a lifetime of debilitating seizures from the time of childhood or adolescence and remains a significant unmet medical need:

30-40%
of all epilepsy diagnoses are DRE[1]

~1.2 million
people in the U.S. are affected by DRE[1]

Only 6.5K
DRE patients get treatment beyond the drugs that failed them[2]

CLOSING THE GAP:
Revolutionizing Seizure Treatment for DRE

The RNS® System is the first and only FDA-approved responsive neuromodulation platform that delivers personalized, real-time seizure treatment, helping people with focal DRE attain unmatched seizure control and a better standard of care.

3-year results from the ongoing post-approval study (PAS) of the NeuroPace RNS System show:

82% median seizure reduction at 3 years[3]

62% median seizure reduction at 6 months[3]

42% seizure freedom for 6+ months[3,*]

3x lower incidence of Sudden Unexpected Death in Epilepsy (SUDEP)[4]

1 in 3 patients did not require intracranial monitoring[3]

The RNS System PAS is the Largest Prospective Study in Neuromodulation for Focal Epilepsy

As the largest FDA-reviewed study in neuromodulation for focal epilepsy,[3,5,6,**] the PAS includes outcomes from:

324 patients

from **32 Level 4 Comprehensive Epilepsy Centers** across the U.S.



1. Chen, Z., et al., JAMA Neurology, 2018.
2. Ostendorf, et al, Neurology, 2022.
3. RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data, seizure freedom at last follow-up is LOCF
4. Compared to placebo arm of ASM trial. 2.3/1000 patient years rate of SUDEP in RNS System prospective studies (AAN Oral Presentation, April 2025) vs 6.9/1000 patient years rate of SUDEP in Anti-seizure Medication (ASM) placebo; Ryvlin et al, Lancet Neurol, 2011
5. Salanova et al., Neurology, 2015
6. DeGiorgio et al, Epilepsia, 2000

* At some point during the study

** Therapies were studied using different study designs. Caution must be exercised when comparing results.

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at http://www.neuropace.com/safety/. Refer to the labeling for a description of the RNS® System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use. ©2025 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA 94043.
NP 250047 Rev1 / Rev. Date: 2025-03